Quick Takeaways
- Spruce Street Capital LP filed SCHEDULE 13G for RELMADA THERAPEUTICS, INC. Common Stock, par value $0.001 per share (RLMD).
- Disclosed ownership: 5.6%.
- Date of event: 31 Dec 2025.
Spruce Street Capital LP - 31 Dec 2025 SCHEDULE 13G Report for RELMADA THERAPEUTICS, INC. Common Stock, par value $0.001 per share (RLMD)
- Filing Manager
- Spruce Street Capital LP
- Reporting Manager
- Spruce Street Capital LP
- Symbol
- RLMD
- Shares outstanding
- 73,360,521 shares
- Disclosed Ownership
- 4,086,181 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 09:15:23 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Spruce Street Capital LP disclosed 5.6% ownership in RELMADA THERAPEUTICS, INC. Common Stock, par value $0.001 per share (RLMD) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 09:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Spruce Street Capital LP | 5.6% | 4,086,181 | 0 | 4,086,181 | /s/ Alex R. Rosen | By: Spruce Street Capital GP LLC, its General Partner, By: Alex R. Rosen, its Co-Managing Member | |
| Alex R. Rosen | 5.6% | 4,086,181 | 0 | 4,086,181 | /s/ Alex R. Rosen | Alex R. Rosen, individually | |
| Simon Basseyn | 5.6% | 4,086,181 | 0 | 4,086,181 | /s/ Simon Basseyn | Simon Basseyn, individually |